Methylation-related metabolic effects of D4 dopamine receptor expression and activation

Nathaniel W Hodgson1, Mostafa I Waly2, Malav S Trivedi3

  • 1Department of Neurology and the F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, 02115, USA.

Translational Psychiatry
|November 14, 2019
PubMed

Insights

Dopamine D4 receptor (D4R) activation influences phospholipid methylation and methionine synthase activity. D4R expression impacts cellular methylation and redox balance, linking neurotransmission to metabolism.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Dopamine D4 receptor (D4R) activation is linked to phospholipid methylation using folate-derived methyl groups.
  • Methionine synthase (MS) is crucial for providing these methyl groups.

Purpose of the Study:

  • To investigate the impact of D4R expression and dopamine on folate-dependent phospholipid methylation (PLM) and MS activity.
  • To assess cellular redox and methylation status in response to D4R activation.

Main Methods:

  • Transfected Chinese hamster ovary (CHO) cells expressing D4R variants (D4.2R, D4.4R, D4.7R) were used.
  • Measurements included PLM, MS activity, methylation cycle intermediates (methionine, SAM, SAH), and redox markers (cysteine, GSH).
  • Global DNA methylation was also assessed.

Main Results:

  • Dopamine increased PLM in D4R-expressing cells, with varying effects based on D4R variant.
  • D4R expression decreased basal MS activity but conferred dopamine-sensitive activity, enhanced by more exon III repeats.
  • Dopamine stimulation increased GSH, SAM, and the SAM/SAH ratio, leading to elevated global DNA methylation.

Conclusions:

  • D4R expression and activation significantly influence MS activity and cellular methylation status.
  • Dopamine modulates cellular redox balance and methylation via D4R signaling.
  • These findings reveal a novel connection between D4R, neurotransmission, and cellular metabolism.

Related Concept Videos

Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
637
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.0K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.1K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.5K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
692